Revista espanola de medicina nuclear e imagen molecular最新文献

{"title":"Role of [18F]FDG PET/CT in the evaluation of inflammatory breast cancer: A case report","authors":"B. Hervás-Sanz , I.E. Sánchez-Rodríguez , A. Fernández-Ortega , P. Perlaza-Jiménez , M. Cortés-Romera , J. Suils-Ramón","doi":"10.1016/j.remnie.2024.500057","DOIUrl":"10.1016/j.remnie.2024.500057","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500057"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solitary adrenal metastasis of breast cancer on [68Ga]Ga-DOTA-TATE PET/CT","authors":"N. Filizoglu , S. Ozguven , F. Dede , H.T. Turoglu , T.Y. Erdil","doi":"10.1016/j.remnie.2024.500061","DOIUrl":"10.1016/j.remnie.2024.500061","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500061"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular [18F]F-FDG PET/MRI in the diagnosis of acute cardiomyopathy inflammatory","authors":"J.R. Garcia, R. Olivero, M. Panelo, L. Mont, L. Pinilla, M.E. Riera, A. Maceira","doi":"10.1016/j.remnie.2024.500038","DOIUrl":"10.1016/j.remnie.2024.500038","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500038"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of fundic accommodation in gastric emptying scintigraphy. Evaluation of its clinical usefulness","authors":"J.R. Infante,&nbsp;A. Utrera,&nbsp;A. Baena,&nbsp;R. Barco,&nbsp;A. Martínez,&nbsp;C. Durán,&nbsp;P. Jiménez,&nbsp;J. Serrano","doi":"10.1016/j.remnie.2024.500051","DOIUrl":"10.1016/j.remnie.2024.500051","url":null,"abstract":"<div><h3>Aim</h3><div>Gastric emptying scintigraphy is used to assess patients with symptoms of dyspepsia or gastroparesis. An alteration of fundus accommodation may explain these symptoms. The aim of this study was to determine the accommodation in gastric emptying scintigraphy studies performed in our institution.</div></div><div><h3>Material and methods</h3><div>50 patients (43 children) referred for gastric emptying assessment were evaluated. After fasting for 8 h, and following international guidelines, egg labeling was performed with 37 mBq of [⁹⁹mTc]Tc-DTPA and administration of standardized food. Areas of interest were defined in the stomach at different times, and the corresponding retention percentages were calculated. Considering the image at time zero, gastric accommodation was qualitatively and quantitatively assessed, calculating the ratio between proximal stomach counts and total counts.</div></div><div><h3>Results</h3><div>Of the 50 patients studied, 32 had normal emptying, 10 had slowed emptying and 8 had accelerated emptying. Within the group of patients with normal emptying, 8 had altered accommodation (25%) and another 8 in the group with abnormal emptying (44%). Applying the ROC curve analysis to quantitative values, the most appropriate cut-off value was 0.785 with <em>p</em> &lt; 0.001, sensitivity 82.4% and specificity 100%.</div></div><div><h3>Conclusion</h3><div>Gastric emptying scintigraphy in addition to determining motility, made it possible to assess both qualitatively and quantitatively the distribution of the radiotracer in the stomach and thus, indirectly, the accommodation in the fundus. It provided added diagnostic information in a simple manner, without protocol changes and allowing more specific treatments to be assessed.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500051"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET/CT for the prediction of biochemical recurrence in prostate cancer","authors":"Seda Gülbahar Ateş ,&nbsp;Bedriye Büşra Demirel ,&nbsp;Esra Kekilli ,&nbsp;Erdem Öztürk ,&nbsp;Gülin Uçmak","doi":"10.1016/j.remnie.2024.500032","DOIUrl":"10.1016/j.remnie.2024.500032","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies.</div></div><div><h3>Methods</h3><div>51 patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses.</div></div><div><h3>Results</h3><div>29 (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level (<em>P</em> <!-->=<!--> <!-->.050), GLCM-sum variance (<em>P</em> <!-->=<!--> <!-->.019), and GLCM-cluster prominence (<em>P</em> <!-->=<!--> <!-->.050) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level (<em>P</em> <!-->=<!--> <!-->.009) and GLCM-sum variance (<em>P</em> <!-->=<!--> <!-->.004) were found as independent predictors of BCR in the multivariate analysis.</div></div><div><h3>Conclusion</h3><div>Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500032"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supernumerary kidney fused to the isthmus of a horseshoe kidney, with subsequent nephroblastoma, identified with dynamic renal scintigraphy","authors":"S. Bondia-Bescós ,&nbsp;L.J. Pregil ,&nbsp;L. Biassoni","doi":"10.1016/j.remnie.2024.500058","DOIUrl":"10.1016/j.remnie.2024.500058","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500058"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases","authors":"X. Ruan ,&nbsp;Y. Gao","doi":"10.1016/j.remnie.2024.500054","DOIUrl":"10.1016/j.remnie.2024.500054","url":null,"abstract":"<div><h3>Aim</h3><div>To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging). According to the results of the first 99mTc-PSMA SPECT/CT imaging for detecting bone metastasis, all cases were divided into two groups: positive group and negative group. The relationship between 99mTc-PSMA imaging and PSA and ALP was analyzed by ROC curve. Fisher exact probability method was used to examine the changes in imaging radioactivity uptake, PSA, and ALP levels in 17 patients after treatment, and <em>P</em> &lt; 0.05 was statistically significant.</div></div><div><h3>Results</h3><div>All 43 patients had different degrees of radioactive concentrations on whole-body bone imaging. The first 99mTc-PSMA SPECT/CT imaging showed positive bone metastases in 31 cases and negative bone metastases in 12 cases. ROC curve analysis of PSA and ALP, AUC were 0.778 and 0.770, respectively. When PSA &gt; 1.13 ng/mL, 99mTc-PSMA SPECT/CT imaging diagnostic sensitivity was 93.55%, and specificity was 66.67%. When ALP was &gt;86U/L, the diagnostic sensitivity of 99mTc-PSMA SPECT/CT imaging was 64.52%, and the specificity was 83.33%. In 17 cases, the PSA level decreased in 7 and increased in 10. There were 10 cases of increased ALP and 7 cases of decreased ALP levels. In the second 99mTc-PSMA imaging lesion, there were 9 cases with decreased or no uptake, and 8 cases with increased uptake or number of lesions. The changes in 99mTc-PSMA uptake by Fisher’s exact probability method were statistically significant (<em>P</em> &lt; 0.05, <em>P</em> = 0.006, and <em>P</em> = 0.006, respectively), and ALP level was not statistically significant (<em>P</em> = 0.563).</div></div><div><h3>Conclusion</h3><div>99mTc-PSMA SPECT/CT imaging can detect PCa bone metastases, which are related to PSA levels. When PSA &gt; 1.13 ng/mL, the sensitivity of diagnosis and detection of positive bone metastases is higher, and when ALP is &gt;86U/L, 99mTc-PSMA imaging has higher specificity.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500054"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low dose radioactive iodine ablation therapy (1.11GBq) for differentiated thyroid cancer in Western Turkey","authors":"B. Karasah Erkek ,&nbsp;H. Sariyildiz Gumusgoz ,&nbsp;A. Oral ,&nbsp;B. Yazici ,&nbsp;A. Akgun","doi":"10.1016/j.remnie.2024.500055","DOIUrl":"10.1016/j.remnie.2024.500055","url":null,"abstract":"<div><h3>Objective</h3><div>Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [131I]-NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90–95 % at 10 years), [131I]-NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation.</div></div><div><h3>Methods</h3><div>Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110 MBq (30 mCi) [131I]-NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed.</div></div><div><h3>Results</h3><div>An excellent response was achieved in 77% of the entire group according to ATA criteria post-ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10 ng/mL and 5.35 ng/mL) were associated with unsuccessful ablation.</div></div><div><h3>Conclusions</h3><div>Our results indicate that a 1110MBq (30mCi) ablation dose is sufficient to achieve an excellent response in most low-risk DTC cases 6–12 months later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 6","pages":"Article 500055"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To evaluate the detection rate of local and whole-body recurrence by integrated [18F]F-PSMA-1007 PET/MR assessment of prostate cancer patients treated with prostatectomy with very low biochemical recurrence (<0.5 ng/ml). Therapeutic implications","authors":"J.R. Garcia,&nbsp;A. Compte,&nbsp;J. Pastor,&nbsp;S. Mourelo,&nbsp;L. Mont,&nbsp;P. Bassa,&nbsp;E. Llinares,&nbsp;M. Soler,&nbsp;E. Valls,&nbsp;T. Blanch,&nbsp;E. Riera","doi":"10.1016/j.remnie.2024.500037","DOIUrl":"10.1016/j.remnie.2024.500037","url":null,"abstract":"<div><h3>Objective</h3><p>To analyse the efficacy of integrated assessment of [¹⁸F]F-PSMA-1007 PET/MRI on the early detection of local recurrence (LR) for prostate cancer patients with PSA levels &lt;0.5<!--> <!-->ng/ml after radical prostatectomy.</p><p>To assess the location of recurrence so that therapy may be tailored to patient.</p></div><div><h3>Methods</h3><p>Prospective study including 35 patients with prostate cancer (PCa), who were referred for a [¹⁸F]F-PSMA-1007 PET/MR after prostatectomy with a very initial PSA value increase (PSA<!--> <!-->&lt;<!--> <!-->0,5<!--> <!-->ng/ml).</p><p>Simultaneous acquisition in a PET/MRI hybrid equipment (SIGNA-GE), 1<!--> <!-->h after administration of 370%<!--> <!-->±<!--> <!-->10% MBq of [¹⁸F]F-PSMA-1007:</p><p>Prostate selective imaging (20<!--> <!-->min): multiparametric PET<!--> <!-->+<!--> <!-->MRI (MRImp): DIXON, T1, T2, diffusion sequences post-gadolinium administration.</p><p>Whole body image (30<!--> <!-->min): PET<!--> <!-->+<!--> <!-->MRI: DIXON, T1, T2, diffusion, STIR sequences.</p><p>A nuclear physician and a radiologist jointly reviewed the studies:</p><p>In order to assess LR, the “Prostate Imaging for Recurrence Reporting” system was used on MRI, as well as the Likert scale on the PET prostate imaging.</p><p>The remaining lesions were classified as N1 and M1a.</p></div><div><h3>Results</h3><p>PET/MRI was positive in 25 patients (71,4%) and negative in 10 patients (28,6%).</p><p>RL was detected in 15 patients (42.9%): in 2 (5.7%) MRI was superior; in 3 (8.6%) PET was superior; integrated PET/MRI showed improved results in 5 patients (14.3%) for the detection of LR.</p><p>Location of recurrences: LR in 11 patients (44.0%); N1 in 10 (40.0%); LR<!--> <!-->+<!--> <!-->N1 (8.0%) in 2; LR<!--> <!-->+<!--> <!-->N1<!--> <!-->+<!--> <!-->M1a in 2 (8.0%).</p><p>In 20 patients (80%) the PET/MRI findings allowed radioguided radiotherapy implementation (11 on LR, and 9 on N1), whereas hormonal treatment was decided in 5 patients (20%) due to multimetastases/spread disease.</p></div><div><h3>Conclusion</h3><p>[¹⁸F]F-PSMA-1007 PET/MRI has a 71.4% recurrence detection rate after prostatectomy with PSA<!--> <!-->&lt;<!--> <!-->0.5<!--> <!-->ng/ml. Its combined PET and MRI study increases the detection of LR by 14.3%, with a high N1<!--> <!-->+<!--> <!-->M1a detection rate (56%), allowing radioguided radiotherapy in 80% of patients.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 5","pages":"Article 500037"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA PET/CT quick procedure guide","authors":"J. Muñoz-Iglesias ,&nbsp;A. Rodríguez-Fernández ,&nbsp;P. Paredes-Barranco ,&nbsp;M. Rodríguez-Fraile ,&nbsp;A. Gómez-Grandef ,&nbsp;M. Simó-Perdigó ,&nbsp;J. Castell-Conesa","doi":"10.1016/j.remnie.2024.500045","DOIUrl":"10.1016/j.remnie.2024.500045","url":null,"abstract":"<div><p>The application of PET/CT with radiopharmaceuticals targeting PSMA is significantly transforming the diagnostic and therapeutic strategies of patients with prostate cancer. In Spain, the availability and access to positron-emitting radiopharmaceuticals targeting Prostate-Specific Membrane Antigen (PSMA) have significantly changed in recent months. These changes are affecting their use in diagnostic procedures. As a result, its use within diagnostic protocols for patients with prostate cancer is undergoing significant modifications. In this collective and cooperative document, the authors have selected the most robust evidence accumulated to date to generate a clinical guide to achieve appropriate use of this technology. A format that presents the most frequent clinical situations and the patient profiles in which PSMA PET/CT plays a significant role or will do so in the immediate future has been chosen. It should be taken into account that regulatory restrictions mediate the current indications for its use in Spain, as well as its current cost and the production capacity of radiopharmaceuticals. The guideline presents a review of the established methodology for optimized imaging with each of the radiopharmaceutical variants targeting PSMA and recommendations for structured and accurate reporting of metabolic findings in combination with CT.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 5","pages":"Article 500045"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}